Roche’s inavolisib meets primary endpoint of PFS in Phase 3 breast cancer trial
Roche, a global leader in pharmaceuticals, announced positive results from its Phase III INAVO120 study, testing the investigational therapy inavolisib in combination with palbociclib (Ibrance) and fulvestrant. This study targeted patients with PIK3CA-mutated, hormone receptor (HR)-positive, HER2-negative, endocrine-resistant, locally advanced or metastatic breast cancer. The trial met its primary endpoint, showing a significant improvement in […]